Ratings Aspen Pharmacare Holdings Limited

Equities

APN

ZAE000066692

End-of-day quote Johannesburg S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
220.7 ^ZAR	+1.98%		+1.70%	+8.46%

Mar. 08	Aspen Pharmacare Holdings Limited Announces Board Changes	CI
Mar. 05	Aspen Pharmacare Holdings Limited Seeks Acquisitions	CI

Summary

The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
The company appears to be poorly valued given its net asset value.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B		B+
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B		B-
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B		B+
SANDOZ GROUP AG	+10.86%	14.09B		-
CIPLA LIMITED	+13.07%	13.64B		B+
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B		B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-4.29%	4.71B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes